ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VIR vs MAZE // RSI-14 & 200D SMA MOMENTUM

Vir Biotechnology Inc. (NASDAQ) VS. Maze Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: VIR 2 — MAZE 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MAZE
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VIR VS. MAZE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VIR MAZE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -19.74% -6.36% -13.38 MAZE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -7.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.40 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 VIR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 49.4 54.4 -5.00 MAZE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.88B $1.69B $193.8M VIR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VIR REV MAZE REV VIR GROSS % MAZE GROSS % VIR FCF MAZE FCF
FY 2025 $68.6M $400.1M 98.0% — -$396.6M -$112.7M
FY 2024 $74.2M $167.5M 98.0% — -$453.7M $74.8M
FY 2023 $86.2M — — — -$778.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VIR // BETA —
MAZE // BETA —